Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1801 to 1815 of 7707 results

  1. Subcutaneous ravulizumab for treating paroxysmal nocturnal haemoglobinuria or atypical haemolytic uraemic syndrome TS ID 11820

      Status ...

    Technology appraisal guidance
    Topic selection

  2. Sacubitril valsartan for treating chronic heart failure with reduced ejection fraction in people under 18 years TS ID 10350

      Status ...

    Technology appraisal guidance
    Topic selection

  3. Macitentan for treating pulmonary arterial hypertension in people 1 month to 17 years TS ID 11805

      Status ...

    Technology appraisal guidance
    Topic selection

  4. Remimazolam for general anaesthesia [ID3796]

      Status ...

    Technology appraisal guidance
    Topic selection

  5. Glucarpidase for reducing toxic plasma methotrexate levels in people aged 28 days and over TS ID 10761

      Status ...

    Technology appraisal guidance
    Topic selection

  6. Vilobelimab for treating COVID-19 TS ID 11815

    Awaiting development [GID-TA11227] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Sabizabulin for treating COVID-19 TS ID 11814

    Awaiting development [GID-TA11226] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Alpelisib with olaparib for treating BRCA wild-type platinum-refractory or -resistant ovarian, fallopian tube or primary peritoneal cancer after 1 to 3 previous treatments TS ID 11830

    Awaiting development [GID-TA11251] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Bardoxolone methyl for treating chronic kidney disease in people 12 years and over with Alport syndrome TS ID 9998

      Status ...

    Technology appraisal guidance
    Topic selection

  10. Pembrolizumab with enzalutamide and androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer TS ID 11810

    Awaiting development [GID-TA11202] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent TS ID 11808

    Awaiting development [GID-TA11200] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Prostate cancer (hormone relapsed, homologous recombination deficiency, metastatic) – rucaparib (after 1 therapy) [ID6127]

    Awaiting development [GID-TA11219] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor TS ID 11822

    Awaiting development [GID-TA11229] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Semaglutide for treating type 2 diabetes and associated peripheral arterial disease TS ID 11791

      Status ...

    Technology appraisal guidance
    Topic selection

  15. Social work interventions for adults with complex needs (including learning disabilities) and mental health needs

    Awaiting development [GID-QS10148] Expected publication date: TBC

    Quality standard
    Awaiting development